C4 Therapeutics Inc (CCCC)

Currency in USD
2.480
+0.040(+1.64%)
Closed·
2.370-0.110(-4.42%)
·
CCCC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.3212.545
52 wk Range
1.6905.170
Key Statistics
Prev. Close
2.44
Open
2.39
Day's Range
2.321-2.545
52 wk Range
1.69-5.17
Volume
3.63M
Average Volume (3m)
2.55M
1-Year Change
1.6393%
Book Value / Share
1.85
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CCCC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.500
Upside
+404.03%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

C4 Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.500
(+404.03% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy6.00+141.94%7.00MaintainNov 06, 2026
Lake Street
Buy11.00+343.55%-New CoverageOct 28, 2026
JPMorgan
Buy10.00+303.23%-New CoverageOct 09, 2026
Barclays
Buy7.00+182.26%5.00MaintainFeb 26, 2026
TD Cowen
Buy---MaintainFeb 26, 2026

C4 Therapeutics Inc SWOT Analysis


Promising Pipeline
Explore C4 Therapeutics' lead candidate CFT1946, a BRAF V600X degrader showing superior efficacy in preclinical studies and early clinical trials
Clinical Progress
Delve into early clinical data revealing encouraging anti-tumor activity and favorable safety profile of CFT1946 compared to historical benchmarks
Market Potential
Learn how CFT1946's unique mechanism and safety profile could position it as a preferred treatment across various BRAF V600 mutant-driven cancers
Analyst Outlook
BMO Capital Markets rates C4 Therapeutics as Outperform with a $20 price target, suggesting significant upside potential from current levels
Read full SWOT analysis

Earnings

Latest Release
Nov 05, 2026
EPS / Forecast
-0.16 / -0.20
Revenue / Forecast
8.47M / 8.82M
EPS Revisions
Last 90 days

CCCC Income Statement

Compare CCCC to Peers and Sector

Metrics to compare
CCCC
Peers
Sector
Relationship
P/E Ratio
−3.6x−7.0x−0.2x
PEG Ratio
−0.060.010.00
Price/Book
1.4x1.8x2.6x
Price / LTM Sales
10.1x15.3x2.6x
Upside (Analyst Target)
-124.6%76.9%
Fair Value Upside
Unlock−9.3%14.9%Unlock

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
25.85M19.68%64.10M
Other Institutional Investors
149.22M80.32%370.07M
Public Companies & Retail Investors
0.000.00%0.00
Total
175.07M100.00%434.17M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Sirenia Capital Management LP7.11%9,335,00023,151
Squadron Capital Management LLC7.10%9,318,68323,110

People Also Watch

8.89
CGEM
-1.98%
5.040
CADL
-1.75%
3.720
TSHA
-1.33%
10.08
JANX
-2.04%
8.340
QTTB
-1.65%

FAQ

What Is the C4 (CCCC) Stock Price Today?

The C4 stock price today is 2.480 USD.

What Stock Exchange Does C4 Trade On?

C4 is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for C4?

The stock symbol for C4 is "CCCC."

What Is the C4 Market Cap?

As of today, C4 market cap is 320.410M USD.

What Is C4's Earnings Per Share (TTM)?

The C4 EPS (TTM) is -0.71.

When Is the Next C4 Earnings Date?

C4 will release its next earnings report on Feb 25, 2027.

From a Technical Analysis Perspective, Is CCCC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has C4 Stock Split?

C4 has split 0 times.

How Many Employees Does C4 Have?

C4 has 104 employees.

What is the current trading status of C4 (CCCC)?

As of Nov 21, 2026, C4 (CCCC) is trading at a price of 2.480 USD, with a previous close of 2.440 USD. The stock has fluctuated within a day range of 2.321 USD to 2.545 USD, while its 52-week range spans from 1.690 USD to 5.170 USD.

What Is C4 (CCCC) Price Target According to Analysts?

The average 12-month price target for C4 is 12.500 USD, with a high estimate of 30 USD and a low estimate of 6 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +404.03% Upside potential.

What Is the CCCC Premarket Price?

CCCC's last pre-market stock price is 2.380 USD. The pre-market share volume is 2,190.000, and the stock has decreased by -0.060, or -2.460%.

What Is the CCCC After Hours Price?

CCCC's last after hours stock price is 2.370 USD, the stock has decreased by -0.110, or -4.420%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.